key: cord-0050785-icgxi37n
authors: Kain, Dylan; McCreight, Elizabeth; Mazzulli, Tony; Gubbay, Jonathan B.; Rea, Elizabeth; Johnstone, Jennie
title: Diagnostic Sensitivity of Nasopharyngeal RT-PCR in a Long-Term Care Home Outbreak
date: 2020-09-29
journal: J Am Med Dir Assoc
DOI: 10.1016/j.jamda.2020.08.018
sha: cd50934519958ca3585f11c4859095d021074ff4
doc_id: 50785
cord_uid: icgxi37n

nan

To the Editor: Since its emergence in late 2019, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has rapidly spread across the world with unprecedented impacts globally. The mainstay of diagnosis remains reverse-transcriptase polymerase chain reaction (RT-PCR); however, uncertainty remains about the sensitivity of these tests, as was recently outlined by Woloshin et al. 1 Only 1 study has used a clinical gold standard to determine a sensitivity of only 66%. 2 As a result, many have adopted policies of serial testing, even in low-to moderate-risk patients, potentially leading to delays in care. Furthermore there is to date no evidence about the specific diagnostic performance in older individuals or in long-term care homes, even though most morbidity and mortality have been in these settings. 3, 4 We sought to better define the true sensitivity of nasopharyngeal testing against a broad clinical definition in a longterm care home setting.

A retrospective chart review of residents from a long-term care home with a large COVID-19 outbreak was conducted. Charts were reviewed to extract, comorbidities, symptoms, and outcomes. The study period was March 1 (before the outbreak in the home) to May 21, 2020 (the day the outbreak was declared over). The case definition used was based on the provincial case definition, 5 and included a broad range of typical and atypical symptoms (fever, cough, chills, myalgias, fatigue, sore throat, rhinorrhea, conjunctivitis, unexplained tachycardia or hypotension, difficulty swallowing, headache, dyspnea, hypoxia, diarrhea, nausea or vomiting, confusion, functional decline, or altered taste and smell). Results were summarized using descriptive statistics. Sensitivity and negative predictive values were also calculated. Research Ethics Board approval for the study was obtained from our institution.

Until April 13, 2020, testing was performed using a published laboratory-developed test targeting the E gene and RdRp of SARS-CoV-2. 6 From April 14 onward, RT-PCR was performed using the Allplex 2019-nCoV Assay (Seegene Inc., Seoul, Republic of Korea), which targets the E, N, and RdRp genes of SARS-CoV-2.

A total of 117 residents were living in the home at the start of the study period, in a mixture of private, semi-private, and 4-person rooms. Four patients refused testing and were excluded, leaving 113 patients to be included, all of whom underwent at least 1 nasopharyngeal swab for Coronavirus Disease 2019 (COVID-19) . The mean age of the residents was 78.3 AE 11.8 years, 45.5% were men, and the rates of comorbidities were as follows: 62% hypertension, 31% cardiovascular disease, 30% diabetes, 29% previous stroke, and 25% chronic lung disease.

Ninety-seven (85.8%) of 113 residents had confirmed COVID-19 infection; 19 patients required hospitalization and 21 died (21.6% case-fatality). There were 5 additional noneCOVID-19 deaths during the study period. In those with confirmed SARS-CoV-2, 68.0% (66/97) had fever, 52.6% (51/97) had cough, 7.2% (7/97) had sore throat or rhinorrhea, 9.3% (9/97) had dyspnea or hypoxia, and 15.5% (15/97) remained asymptomatic throughout the study period.

Between March 20 and April 13, symptomatic residents were tested, and then after April 14 a combination of symptomatic testing and asymptomatic screening was conducted. A flowchart of testing is outlined in Supplementary Figure 1 .

To calculate sensitivity, we excluded those who remained asymptomatic and also had negative SARS-CoV-2 testing (7 residents), as they were felt to represent true negatives, leaving 106 residents included (Figure 1 ). Of the 97 positive residents, 96 were positive on the first test with a resulting sensitivity of 90.6% (96/ 106).

Despite multiple previous reports suggesting low sensitivity of RT-PCR for SARS-CoV-2 by nasopharyngeal swab, 2,7,8 here we report a relatively high sensitivity (90.6%). A major strength of our study is that by using a nonePCR-based gold standard, we can avoid the bias toward positive PCR. 7, 8 The high attack rate in the home and lack of other circulating viruses at the time allowed for limited confounding that may have been seen in previous studies. 2 Applying these results to a similar population, not in outbreak, and thus with a lower pre-test probability of infection (eg, 10%), results in a high negative predictive value (99%) and thus can adequately rule out disease.

Caution, however, should be taken in extrapolating our results to other populations, because there is evidence 9 that older individuals have higher viral loads and thus may have higher rates of detection than other populations. Another limitation was that given the emerging nature of the pandemic, tests were done at different laboratories and on different machines over the course of the study, and these could have different sensitivities, affecting the generalizability of the results.

Overall, our results suggest RT-PCR for SARS-CoV-2 by nasopharyngeal swab has a high sensitivity in this cohort of older longterm care home residents. 

False negative tests for SARS-CoV-2 infection e challenges and implications

Correlation of chest CT and RT-PCR testing in Coronavirus Disease 2019 (COVID-19) in China: A report of 1014 cases

Mortality associated with COVID-19 outbreaks in care homes: Early international evidence

Daily epidemiologic summary: COVID-19 in Ontario

COVID-19 Reference Document for Symptoms

Detection of 2019 novel coronavirus (2019-nCoV) by real-time RT-PCR

Sensitivity of chest CT for COVID-19: Comparison to RT-PCR

Diagnosis of the Coronavirus disease (COVID-19): rRT-PCR or CT?

Impact of SARS-CoV-2 viral load on risk of intubation and mortality among hospitalized patients with Coronavirus Disease

 Supplementary Fig. 1 . Flowchart of testing.